BioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conference
- None.
- None.
Insights
The projection of Leqembi's sales reaching JPY 290 billion by FY 2026 and JPY 1.6 trillion by FY 2032 indicates a significant market opportunity for BioArctic AB and its partner Eisai. This forecast suggests a strong revenue stream and could potentially lead to upward valuation adjustments for both companies involved. Investors should consider the growth trajectory of the Alzheimer's treatment market, as well as the competitive landscape and pricing strategies. It's also crucial to monitor the adoption rates of Leqembi among healthcare providers and patients, alongside potential market expansion through regulatory approvals in additional countries.
From a financial perspective, the sales figures presented for Leqembi have the potential to impact BioArctic AB's profitability and investor sentiment. The projected JPY 290 billion in sales by FY 2026 could significantly influence the company's earnings per share and overall financial health. Long-term forecasts, such as the JPY 1.6 trillion by FY 2032, also suggest confidence in the drug's sustained market presence and effectiveness. Investors should analyze the underlying assumptions of these projections, the cost structure of BioArctic AB and the potential impact on its cash flows and dividend policies.
The designation of Leqembi as the world's first fully approved disease-modifying treatment for Alzheimer's disease underscores its importance in the medical field. The high sales projections reflect expectations of its efficacy and the unmet need in the Alzheimer's treatment landscape. Stakeholders should evaluate the clinical data supporting Leqembi's approval, its safety profile and its comparative effectiveness against other treatments. Additionally, understanding the prevalence of Alzheimer's and demographic trends could provide insights into the potential patient population and market size.
Eisai's presentation can be found on https://www.eisai.com/ir/library/presentations/index.html.
This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, on March 7, 2023, at 06:30 a.m. CET.
For further information, please contact:
Oskar Bosson, VP Communications and IR
E-mail: oskar.bosson@bioarctic.com
Phone: +46 70 410 71 80
Jiang Millington, Director Corporate Communication and Social Media
E-mail: jiang.millington@bioarctic.com
Phone: +46 79 33 99 166
About lecanemab (generic name,
Lecanemab (Leqembi) is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in the
U.S. : For the treatment of Alzheimer's disease (AD). It should be initiated in patients with mild cognitive impairment or mild dementia stage of disease. Please see fullU.S. Prescribing Information.Japan : For slowing progression of mild cognitive impairment (MCI) and mild dementia due to AD.China : For the treatment of MCI due to AD and mild AD dementia.
About the collaboration between BioArctic and Eisai
Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody lecanemab back-up for Alzheimer's disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region under certain conditions and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with regulatory approvals, and sales milestones as well as royalties on global sales.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.se.
[1] Simulation not to be seen as guidance according to Eisai
The following files are available for download:
BioArctic’s partner Eisai presents updated sales simulation for Leqembi® at its annual press conference |
View original content:https://www.prnewswire.com/news-releases/bioarctics-partner-eisai-presents-updated-sales-simulation-for-leqembi-at-its-annual-press-conference-302082463.html
SOURCE BioArctic
FAQ
What is the projected sales figure for Leqembi in FY2026 according to Eisai's simulation?
What is the projected sales figure for Leqembi in FY2032 according to Eisai's simulation?
Where can Eisai's presentation on Leqembi sales be found?
